Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 55Specimen Handling 49Oxaliplatin 48Leucovorin 45Magnetic Resonance Spectroscopy 44Bevacizumab 42Gemcitabine 38Irinotecan 29Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 23Biopsy 23pembrolizumab 22Paclitaxel 21Capecitabine 19atezolizumab 18Taxes 14Folfox protocol 13Carboplatin 13durvalumab 12Radiotherapy 12Cyclophosphamide 12fludarabine 11X-Rays 11dehydroftorafur 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Radiation 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Itraconazole × Gastrointestinal × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡